Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 670 across all filing types
Latest filing 2020-10-28 Governance Information
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
信息披露暂缓与豁免管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy titled 'Information Disclosure Delay and Exemption Management System' issued by 奥锐特药业股份有限公司. It outlines procedures, conditions, responsibilities, and penalties related to delaying or exempting information disclosure in compliance with securities laws and stock exchange rules. It is a governance-related document focusing on internal rules and compliance processes rather than financial results, audit, or shareholder meeting materials. The document length is 2060 characters, which is relatively short but contains substantive policy content rather than a mere announcement. There is no indication of financial data, earnings, voting results, or legal proceedings. Therefore, the document best fits the category of Governance Information (CGR).
2020-10-28 Chinese
关于使用闲置自有资金进行委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 奥锐特药业股份有限公司 regarding the use of idle self-owned funds for entrusted financial management. It details the amount, purpose, risk control, and approval procedures of the entrusted financial management. The document includes financial figures but does not contain comprehensive financial statements or detailed financial analysis. It is a formal announcement about a financing activity related to cash management and investment of idle funds, not a full financial report or audit. The document is relatively short (2030 characters) and focuses on a capital/financing update rather than an earnings release or annual/interim report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-10-28 Chinese
关于召开2020年第二次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2020 second extraordinary general meeting of shareholders, detailing the meeting date, voting methods, agenda items, and procedural instructions. It includes information on proxy voting and meeting logistics but does not contain any financial statements or results. The document is an announcement related to a shareholders' meeting rather than the meeting materials or voting results themselves. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2020-10-28 Chinese
突发危机事件应急管理制度
Governance Information Classification · 95% confidence The document is titled as an emergency management system for crisis events of a company, 奥锐特药业股份有限公司. It outlines policies, organizational structure, risk categories, response measures, and responsibilities related to managing sudden crisis events. There is no indication of financial data, earnings, audit results, or regulatory filings. It is a governance-related internal policy document rather than a report or announcement. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The content is about governance practices and internal control mechanisms for crisis management, which aligns with Governance Information (CGR). The document length is sufficient and contains detailed governance procedures, not a brief announcement or certification. Therefore, the best classification is Governance Information (CGR).
2020-10-28 Chinese
内幕信息知情人登记管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled '内幕信息知情人登记管理制度' (Insider Information Insider Registration Management System) issued by 奥锐特药业股份有限公司. It outlines the definitions, responsibilities, confidentiality obligations, and registration procedures for insiders who have access to material non-public information. The content focuses on compliance with securities laws, insider trading prohibitions, and internal controls related to insider information management. There are no financial statements, earnings data, or investor presentations. It is not an announcement of a report but a governance and compliance policy document. Therefore, it fits best under Governance Information (CGR), which covers internal rules and governance practices related to company operations and compliance.
2020-10-28 Chinese
累积投票制实施细则
Governance Information Classification · 95% confidence The document is titled as implementation rules for cumulative voting system at a company, detailing governance procedures for board and supervisory board elections. It references company law, securities law, and governance codes, and outlines nomination, voting, and election procedures for directors and supervisors. There is no financial data, no report or announcement of financial results, no mention of annual or interim reports, no audit information, no legal proceedings, no capital changes, no voting results announcement, and no executive changes. The document is a governance-related internal regulation or guideline. Therefore, it fits best under Governance Information (CGR). The document length is 3273 characters, which is relatively short but contains substantive governance content, not just an announcement or notice. Hence, the classification is CGR with high confidence.
2020-10-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.